NACDS taps author to deliver keynote address at annual meeting
ALEXANDRIA, Va. The National Association of Chain Drug Stores announced via the social networking site Twitter that author and business consultant Jim Collins will serve as the keynote speaker on April 27 for the association’s 2010 annual meeting in Palm Beach, Fla.
“We are delighted to have such a renowned author as Jim Collins headlining our Annual Meeting business program this year,” said NACDS president and CEO Steve Anderson. “His business expertise will offer diverse attendees – including retailers, front-end suppliers and pharmacy suppliers – a unique perspective on best practices and provide insights on how companies can succeed.”
Collins has authored or co-authored four books—including the classic “Built to Last,” and the New York Times bestseller, “Good to Great: Why Some Companies Make the Leap…And Others Don’t.” Collins’ latest book, “How the Mighty Fall: And Why Some Companies Never Give In,” was released in spring 2009. His work has been featured in Fortune, The Economist, Fast Company, USA Today, Industry Week, BusinessWeek, Newsweek, Inc., and Harvard Business Review.
Collins began his research and teaching career on the faculty of Stanford’s Graduate School of Business, where he received the Distinguished Teaching Award. After seven years at Stanford, Collins returned to his hometown of Boulder, Colo., to found his management research laboratory.
Report; N.Y. seeks to prohibit doctors from accepting gifts from drug companies
ALBANY, N.Y. New York Gov. David Paterson hopes to put an end to gifts from drug companies to doctors, according to published reports.
The Associated Press reported Sunday that Paterson proposed legislation that would prohibit drug makers from giving doctors such gifts as pens and free meals to persuade them to prescribe their drugs. Drug companies that violated the ban would be fined between $15,000 and $250,000, while healthcare professionals would be fined $5,000 to $10,000. Nine states so far have laws on the books that prohibit the practice.
According to the AP article, patient-advocacy organizations such as AARP are supporting the legislation, while the Pharmaceutical Research and Manufacturers of America, which represents the branded drug industry, opposes it.
Acorda appoints EVP commercial development
HAWTHORNE, N.Y. The founder of a consulting firm has joined the executive board of Acorda Therapeutics, the drug maker announced Monday.
Lauren Sabella will work as Acorda’s EVP commercial development, reporting to president and CEO Ron Cohen and assuming responsibility for Acorda’s commercial operations such as marketing, sales and managed markets.
Before working for Acorda, Sabella was founder and principal of Tugboat Consulting Group, which assisted companies in commercialization. She also worked as VP commercial development for Altus Pharmaceuticals and served in various positions at Boehringer Ingelheim Pharmaeuticals for 18 years.
“I’m delighted to welcome Lauren Sabella to Acorda’s management team,” Cohen said. “Lauren has an impressive record of achievement in the pharmaceutical industry, including responsibility for launching and managing several high-performing products.”